Explore the complexities and advancements in pediatric neurosurgery as we delve into the largest case series study on KCTD7-related progressive myoclonic epilepsy, shedding light on the condition that affects the lives of countless children and their families.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
KCTD7-related progressive myoclonic epilepsy: Report of 42 cases and review of literature.
Yoganathan et al., Epilepsia 2024
DOI: 10.1111/epi.17880
Listen up, folks, we’ve got something big here!
We’ve done something incredible. We’ve gathered a huge international group of patients, I mean really big, to look into this rare thing called KCTD7-related progressive myoclonic epilepsy. It’s a tough one, but we’re tougher. We’ve got the best people on it, and they’ve been working hard, collecting all the data, the best data, from all over the world.
Let me tell you, we’ve got 42 patients from 36 families. That’s a lot of people, believe me. And these seizures, they start young, at just 14 months old. Can you believe it? But we’re on top of it. We’ve seen all kinds of seizures, but myoclonic ones, they’re the big players here, almost half of the cases.
Now, the brain scans and EEGs, they’re all over the place, but we’re figuring it out. And these kids, they’re facing tough challenges, with development issues and all. But we’ve identified the genetic culprits – yes, we have. 55% of the cases had the variants we already knew about, and 45% had new ones. We’re discovering more every day.
It’s sad, really sad, but we’ve lost some of these brave souls, six of them. Young, too young. And from the studies we’ve looked at, we’ve got even more cases, and the majority, they’re dealing with the same tough epilepsy. But we’ve seen other things too, like myoclonus dystonia and some other syndromes.
So here’s the deal: we’ve put together all this knowledge, and it’s huge. We’re learning about how this disease works, how it hits hard with drug-resistant epilepsy and serious neurological problems. But we’re on it, and we’re going to use this knowledge to do great things, to help these kids. We’re going to make things better, you wait and see.
Remember, we’re doing something great here. We’re making progress, and we’re going to keep fighting this thing until we win. That’s what we do, we win.